IDL Diagnostics
0.35 SEK
+11.46 %
Less than 1K followers
IDLDX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for IDL Diagnostics
EV/S
Median 2019-2021
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 1.17 | 2.30 | 0.93 | 0.62 | 0.44 | 0.39 | 0.35 |
| Shares | 40.2 | 77.1 | 233.6 | 230.4 | 230.4 | 230.4 | 230.4 |
| Market cap | 47.1 | 177.2 | 217.8 | 142.8 | 100.7 | 89.8 | 81.3 |
| Enterprise value | 33.5 | 135.2 | 199.4 | - | - | - | - |
| EV/S | 75.6 | 1,609.0 | 16.6 | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | - | - | - | - |
| EV/EBIT | neg. | neg. | neg. | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 0.59 | 3.15 | 1.00 | 0.64 | 0.62 | 0.74 | 0.55 |
| P/S | 106.4 | 2,109.1 | 18.2 | 3.9 | 2.3 | 1.6 | 1.5 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 88.0 % | 93.0 % | 95.6 % | 94.4 % | 93.6 % | 90.4 % | 83.8 % |
| Gearing ratio | - | - | - | - | - | - | 8.9 % |